Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001562180-24-006767
Filing Date
2024-09-11
Accepted
2024-09-11 16:00:27
Documents
1
Period of Report
2024-09-09

Document Format Files

Seq Description Document Type Size
1 PRIMARY DOCUMENT primarydocument.html 4  
1 PRIMARY DOCUMENT primarydocument.xml 4 3491
  Complete submission text file 0001562180-24-006767.txt   4965
Mailing Address 500 TECHNOLOGY SQUARE SUITE 700 CAMBRIDGE MA 02139
Business Address 500 TECHNOLOGY SQUARE SUITE 700 CAMBRIDGE MA 02139 617-586-3100
Foghorn Therapeutics Inc. (Issuer) CIK: 0001822462 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 500 TECHNOLOGY SQUARE SUITE 700 CAMBRIDGE MA 02139
Business Address
Bellon Steven F. (Reporting) CIK: 0001831749 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-39634 | Film No.: 241292558